Synthetic circRNAs could be designed to mimic tumor-suppressive circRNAs, to act as stable “immune adjuvants” activating RIG-I or STING pathways, or even to encode short immunomodulatory peptides through small open reading frames (sORFs). The gene discussed is STING1; the disease is neoplasm.